<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01286220</url>
  </required_header>
  <id_info>
    <org_study_id>STU 012010-059</org_study_id>
    <nct_id>NCT01286220</nct_id>
  </id_info>
  <brief_title>Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Controlled, Evaluator-blinded Study to Evaluate the Efficacy of Dilute Bleach Baths on Skin Disease Control in Pediatric Patients With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Medical Center Dallas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if twice weekly 10 minute dilute bleach baths
      decreases disease severity in patients with moderate to severe atopic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    the study was terminated due to participant drop out
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eczema Area and Severity Index Score (EASI)</measure>
    <time_frame>Change in EASI score from baseline at 1 month and 3 month follow ups</time_frame>
    <description>EASI score is recorded at baseline, 1 month and 3 month follow ups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Assessment (IGA)</measure>
    <time_frame>Change in IGA score from baseline at 1 month and 3month follow ups</time_frame>
    <description>IGA scores are recorded at baseline, 1 month and 3 month follow ups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Moderate to Severe Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Dilute bleach baths</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dilute bleach baths</intervention_name>
    <description>Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.</description>
    <arm_group_label>Dilute bleach baths</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Water</intervention_name>
    <description>Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.</description>
    <arm_group_label>Water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2-17 years of age at time of consent. A parent or legal guardian will be required to
             consent and authorize their enrollment in the study.

          -  Male or female of any ethnic background.

          -  English or Spanish speaking.

          -  A clinical diagnosis of atopic dermatitis for at least 6 months prior to enrollment.

          -  Must have moderate to severe atopic dermatitis as rated by the EASI score.

          -  Able to adhere to study visit schedule and other protocol requirements.

          -  Patients and/or family members must agree to not use any other prescription or over
             the counter medications other than the ones prescribed by the study protocol.

        Exclusion Criteria:

          -  Clinical evidence of bacterial or viral superinfection on first visit.

          -  Have received phototherapy within 2 months prior to enrollment.

          -  Have received any systemic medication for atopic dermatitis or any that may affect
             evaluation of atopic dermatitis within 2 months prior to enrollment.

          -  Have a known hypersensitivity response, including anaphylaxis, to any of the topicals
             used for treatment (i.e. topical steroids, bleach)

          -  Participation in another clinical trial using an investigational agent or procedure.

          -  Pregnant or planning pregnancy or surgery during the participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Medical Center of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics. 2009 May;123(5):e808-14. doi: 10.1542/peds.2008-2217.</citation>
    <PMID>19403473</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>January 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2011</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

